Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.

Biotechnology

Abata Therapeutics

Samantha Singer

Stephen Fair

Leonard Dragone

Sandy Lazzari

Reut Brauner

Alec Silverman

Bethan Chilton

Amina Abbadi

Ellen Cahir-McFarland

Christina Strange

Cristina Musselli

Cristin Berkey

John Trzupek

The Advisory Team at Abata Therapeutics provides strategic guidance and expert insights to inform the development and execution of the company's innovative therapies for autoimmune diseases. Comprised of seasoned professionals with deep expertise in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and biomarkers, they play a crucial role in shaping the scientific and clinical directions of Abata's programs, including their lead initiative in progressive MS and early-stage projects in Type 1 Diabetes and inclusion body myositis.

Advisory Team

Research and Development

Leadership Team

Advisory Team

About

Team members

Other teams at Abata Therapeutics

Research and Development

Leadership Team